Circulating Cell-Free DNA in Breast Cancer: Searching for Hidden Information Towards Precision Medicine

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Feb 13

PMID 33578793

Citations 19

Authors

Maria Panagopoulou

Manel Esteller

Ekaterini Chatzaki

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) is a leading cause of death between women. Mortality is significantly raised due to drug resistance and metastasis, while personalized treatment options are obstructed by the limitations of conventional biopsy follow-up. Lately, research is focusing on circulating biomarkers as minimally invasive choices for diagnosis, prognosis and treatment monitoring. Circulating cell-free DNA (ccfDNA) is a promising liquid biopsy biomaterial of great potential as it is thought to mirror the tumor's lifespan; however, its clinical exploitation is burdened mainly by gaps in knowledge of its biology and specific characteristics. The current review aims to gather latest findings about the nature of ccfDNA and its multiple molecular and biological characteristics in breast cancer, covering basic and translational research and giving insights about its validity in a clinical setting.

Citing Articles

BRCA1 & BRCA2 methylation as a prognostic and predictive biomarker in cancer: Implementation in liquid biopsy in the era of precision medicine.

Panagopoulou M, Panou T, Gkountakos A, Tarapatzi G, Karaglani M, Tsamardinos I Clin Epigenetics. 2024; 16(1):178.

PMID: 39643918 PMC: 11622545. DOI: 10.1186/s13148-024-01787-8.

Correlation between plasma ccfDNA, mtDNA changes, CTCs, and epithelial-mesenchymal transition in breast cancer patients undergoing NACT.

Celik B, Peker Eyuboglu I, Koca S, Ugurlu M, Alan O, Gullu Amuran G Turk J Med Sci. 2024; 54(4):652-665.

PMID: 39295614 PMC: 11407343. DOI: 10.55730/1300-0144.5834.

DNA-Binding Proteins and Passenger Proteins in Plasma DNA-Protein Complexes: Imprint of Parental Cells or Key Mediators of Carcinogenesis Processes?.

Tutanov O, Shefer A, Shefer E, Ruzankin P, Tsentalovich Y, Tamkovich S Int J Mol Sci. 2024; 25(10).

PMID: 38791202 PMC: 11121045. DOI: 10.3390/ijms25105165.

Colorimetric and Electrochemical Dual-Mode Detection of Thioredoxin 1 Based on the Efficient Peroxidase-Mimicking and Electrocatalytic Property of Prussian Blue Nanoparticles.

Kim J, Kim J, Thamilselvan A, Nam K, Kim M Biosensors (Basel). 2024; 14(4).

PMID: 38667178 PMC: 11047952. DOI: 10.3390/bios14040185.

Blood Plasma Circulating DNA-Protein Complexes: Involvement in Carcinogenesis and Prospects for Liquid Biopsy of Breast Cancer.

Shefer A, Tutanov O, Belenikin M, Tsentalovich Y, Tamkovich S J Pers Med. 2023; 13(12).

PMID: 38138918 PMC: 10744380. DOI: 10.3390/jpm13121691.

References

Kioulafa M, Balkouranidou I, Sotiropoulou G, Kaklamanis L, Mavroudis D, Georgoulias V . Methylation of cystatin M promoter is associated with unfavorable prognosis in operable breast cancer. Int J Cancer. 2009; 125(12):2887-92. DOI: 10.1002/ijc.24686. View

Shen J, Platek M, Mahasneh A, Ambrosone C, Zhao H . Mitochondrial copy number and risk of breast cancer: a pilot study. Mitochondrion. 2009; 10(1):62-8. PMC: 5040184. DOI: 10.1016/j.mito.2009.09.004. View

Yu D, Tong Y, Guo X, Feng L, Jiang Z, Ying S . Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis. Front Oncol. 2019; 9:95. PMC: 6405437. DOI: 10.3389/fonc.2019.00095. View

Ellinger J, Muller D, Muller S, Hauser S, Heukamp L, von Ruecker A . Circulating mitochondrial DNA in serum: a universal diagnostic biomarker for patients with urological malignancies. Urol Oncol. 2010; 30(4):509-15. DOI: 10.1016/j.urolonc.2010.03.004. View

Kidess E, Jeffrey S . Circulating tumor cells versus tumor-derived cell-free DNA: rivals or partners in cancer care in the era of single-cell analysis?. Genome Med. 2013; 5(8):70. PMC: 3979136. DOI: 10.1186/gm474. View

Chen C, Dhanda R, Tseng W, Forsyth M, Patt D . Evaluating use characteristics for the oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. J Oncol Pract. 2013; 9(4):182-7. PMC: 3710166. DOI: 10.1200/JOP.2012.000638. View

Agostini M, Enzo M, Bedin C, Belardinelli V, Goldin E, Del Bianco P . Circulating cell-free DNA: a promising marker of regional lymphonode metastasis in breast cancer patients. Cancer Biomark. 2012; 11(2-3):89-98. DOI: 10.3233/CBM-2012-0263. View

Cristofanilli M . Circulating tumor cells, disease progression, and survival in metastatic breast cancer. Semin Oncol. 2006; 33(3 Suppl 9):S9-14. DOI: 10.1053/j.seminoncol.2006.03.016. View

Liggett T, Melnikov A, Marks J, Levenson V . Methylation patterns in cell-free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patients. Int J Cancer. 2010; 128(2):492-9. PMC: 2970661. DOI: 10.1002/ijc.25363. View

10.

Sharma G, Mirza S, Parshad R, Gupta S, Ralhan R . DNA methylation of circulating DNA: a marker for monitoring efficacy of neoadjuvant chemotherapy in breast cancer patients. Tumour Biol. 2012; 33(6):1837-43. DOI: 10.1007/s13277-012-0443-y. View

11.

Vagner T, Spinelli C, Minciacchi V, Balaj L, Zandian M, Conley A . Large extracellular vesicles carry most of the tumour DNA circulating in prostate cancer patient plasma. J Extracell Vesicles. 2018; 7(1):1505403. PMC: 6084494. DOI: 10.1080/20013078.2018.1505403. View

12.

Widschwendter M, Evans I, Jones A, Ghazali S, Reisel D, Ryan A . Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Med. 2017; 9(1):115. PMC: 5740791. DOI: 10.1186/s13073-017-0499-9. View

13.

Bronkhorst A, Wentzel J, Aucamp J, van Dyk E, du Plessis L, Pretorius P . Characterization of the cell-free DNA released by cultured cancer cells. Biochim Biophys Acta. 2015; 1863(1):157-65. DOI: 10.1016/j.bbamcr.2015.10.022. View

14.

Arko-Boham B, Aryee N, Blay R, Owusu E, Tagoe E, Doris Shackie E . Circulating cell-free DNA integrity as a diagnostic and prognostic marker for breast and prostate cancers. Cancer Genet. 2019; 235-236:65-71. DOI: 10.1016/j.cancergen.2019.04.062. View

15.

Zachariah R, Schmid S, Buerki N, Radpour R, Holzgreve W, Zhong X . Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. Obstet Gynecol. 2008; 112(4):843-50. DOI: 10.1097/AOG.0b013e3181867bc0. View

16.

Lo Y, Zhang J, Leung T, Lau T, Chang A, Hjelm N . Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet. 1999; 64(1):218-24. PMC: 1377720. DOI: 10.1086/302205. View

17.

Sadovska L, Santos C, Kalnina Z, Line A . Biodistribution, Uptake and Effects Caused by Cancer-Derived Extracellular Vesicles. J Circ Biomark. 2017; 4:2. PMC: 5572990. DOI: 10.5772/60522. View

18.

Chimonidou M, Strati A, Malamos N, Georgoulias V, Lianidou E . SOX17 promoter methylation in circulating tumor cells and matched cell-free DNA isolated from plasma of patients with breast cancer. Clin Chem. 2012; 59(1):270-9. DOI: 10.1373/clinchem.2012.191551. View

19.

Robbins P, Morelli A . Regulation of immune responses by extracellular vesicles. Nat Rev Immunol. 2014; 14(3):195-208. PMC: 4350779. DOI: 10.1038/nri3622. View

20.

Anker P, Lefort F, Vasioukhin V, Lyautey J, LEDERREY C, Chen X . K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. Gastroenterology. 1997; 112(4):1114-20. DOI: 10.1016/s0016-5085(97)70121-5. View